Clinical practice guideline for lung cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 4, 2010, Pages 609-612

  Hayakawa, Kazushige ^a   Tsuboi, Masahiro ^b  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

Author keywords

Clinical practice guideline; Non small cell lung cancer; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; MOLECULAR THERAPY AGENT;

ARTICLE; BONE METASTASIS; BRONCHUS CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; EARLY CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; POSTOPERATIVE CARE; PRACTICE GUIDELINE; STANDARD;

EID: 79960815669     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. The International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004.
2. Hotta K, Matsuo K, Ueoka H, et al: Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 22:3860-3867, 2004. (Pubitemid 41079866)
3. Hamada C, Ohta M, Wada H, et al: Survival benefit of oral UFT for adjuvant chemotherapy after complete resected non-small-cell lung cancer. J Clin Oncol 22:617, 2004.
4. Hotta K, Matsuo K, Ueoka H, et al: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:3852-3859, 2004. (Pubitemid 41079865)
5. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage grouping in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706-714, 2007. (Pubitemid 47357522)
6. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009.
7. Morita S, Okamoto I, Kobayashi K, et al: Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15:4493-4498, 2009.
8. Kim ES, Hirsh V, Mok T, et al: Gefitinb versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 372:1809-1818, 2008.
9. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):an open label, randomised phase 3 trial. Lancet Oncol 11(2):121-128, 2009.
10. Langer C and Hirsh V: Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer 67:4-11, 2010.